Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

AstraZeneca PLC Add to portfolio

LON100:AZN, Aug 23, 08:29 UTC

Latest LON100:AZN News

Filter your feed

Apply Filter

Wednesday, August 21


News

AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study

AZN AZN

BenzingaAugust 21, 2019, 1:04 PM UTC. AstraZeneca plc (NYSE: AZN) faced a clinical setback in a study evaluating a combo drug regimen in non-small cell lung cancer, or NSCLC. AstraZeneca said a Phase 3 study dubbed NEPTUNE that evaluated its PD-LI inhibitor Imfinzi in combination with tremelimumab, an anti-CTLA4 antibody, versus platinum-based chemotherapy – the current standard-of-care- in previously untreated Stage IV NSCLC did not meet the primary endpoint of improving overall survival. The company noted that the primary analysis population was patients with a high tumor mutational burden. The safety and tolerability profile of the combo, however, was consistent with previous trials. AstraZeneca said it intends to do a deep analysis of the vast clinical and biomarker data from the trial to gain further insights to improve Immuno-oncology approaches for patients with metastatic NSCLC. Imfinzi is also being tested as monotherapy in a Phase 3 trial, dubbed PEARL, and in combination with chemotherapy with or without tremelimumab in the Phase 3 trial, dubbed POSEIDON, as part of an extensive late-stage Immuno-oncology program in Stage IV NSCLC.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

The AstraZeneca share price is at all-time highs. Should investors be wary?

AZN AZN

Amid a choppy market environment, shares of AstraZeneca (LSE: AZN) are performing extremely well. But is this a reason to buy them at their current price? Let’s examine the reasons behind the stock’s performance, as well as whether the current valuation represents an attractive investment opportunity. Priced at 7,327p a share, the stock is currently trading at all-time highs, and it’s easy to see why. Over the last few years, AstraZeneca has been increasing its investment in its oncology division, and these trading results are evidence of that.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

AstraZeneca’s combination lung cancer treatment fails clinical trial

AZN AZN

A combination of AstraZeneca’s lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday. The late-stage clinical trial was testing Imfinzi, chemically known as durvalumab, along with another treatment, tremelimumab, and compared the combination to platinum-based chemotherapy to treat patients whose cancer had spread beyond the lungs. “This is clearly disappointing, albeit we do not think hopes were especially high for the durvalumab plus tremelimumab combination given the relatively poor data shown by the combination to date,” said Liberum analyst Graham Doyle. Imfinzi, which was the first immunotherapy to be approved in the stage III lung cancer setting, targets the PD-L1 protein on tumour cells, while tremelimumab targets the CTLA-4 protein.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial
News

AstraZeneca faces setback in lung cancer drug trial

AZN AZN

for early stage lung cancer, and the Anglo Swedish drugmaker has been rolling out trials combining it with different immunotherapy drugs to assess its effectiveness at treating later stages of the disease. AstraZeneca has disclosed a setback for one of its key cancer treatments, saying a trial involving immunotherapy drug Imfinzi was no more effective than regular chemotherapy at treating advanced lung cancer.

Read Full Details

Topics:
  • Business
  • Health
News

AstraZeneca faces setback in lung cancer drug trial

AZN AZN

for early stage lung cancer, and the Anglo Swedish drugmaker has been rolling out trials combining it with different immunotherapy drugs to assess its effectiveness at treating later stages of the disease. AstraZeneca has disclosed a setback for one of its key cancer treatments, saying a trial involving immunotherapy drug Imfinzi was no more effective than regular chemotherapy at treating advanced lung cancer.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

UPDATE 2-AstraZeneca Imfinzi combination fails advanced lung cancer study

AZN AZN

Aug 21 (Reuters) - A combination of AstraZeneca's lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday. The late-stage clinical trial was testing Imfinzi, chemically known as durvalumab, along with another treatment tremelimumab and compared the combination to platinum-based chemotherapy to treat patients whose cancer had spread beyond the lungs. "This (the result) is clearly disappointing, albeit we do not think hopes were especially high for the durvalumab plus tremelimumab combination given the relatively poor data shown by the combination to date," said Liberum analyst Graham Doyle. Imfinzi, which was the first immunotherapy to be approved in the stage III lung cancer setting, targets the PD-L1 protein on tumour cells, while tremelimumab targets the CTLA-4 protein.

Read Full Details

Topics:
  • Business
  • Health
  • Financial

Tuesday, August 20


News

UPDATE 1-Weak pound, AstraZeneca push FTSE higher

AZN AZN

* FTSE 100 up 0.4%, FTSE 250 up 0.2%. * BHP falls after warning on demand (Ads news items, analyst comments, updates share prices). The FTSE 250 gained 0.2% by 0733 GMT. AstraZeneca rose 1.7% and was the biggest boost to the blue-chip index after its Farxiga diabetes drug met the main goals of the late-stage study into its use on heart-failure sufferers. Constituents of the FTSE which book a major chunk of their earnings in dollars, including Unilever and Diageo , gained as worries about the future course of Brexit kept sterling under pressure, although the currency's fall was not as steep as in recent times.

Read Full Details

Topics:
  • Business
  • Financial
News

UPDATE 1-European shares gain for third straight session, AstraZeneca boosts

AZN EURJPY +7 more AZN EURJPY EURCAD AZN EURZAR EURUSD EURAUD EURNZD EURGBP

* Banks, miners keep gains in check (For a live blog on European stocks, type LIVE/ in an Eikon news window). Aug 20 (Reuters) - European shares rose for the third straight session on Tuesday, building on a recovery since late last week as British drugmaker AstraZeneca gained on positive data from a late-stage study. "The underlying fears of a recession are pushing investors to defensive stocks (healthcare, consumer staples and real estate). Last week there were wild swings in markets so investors are probably trying to get ahead of that," Spreadex analyst Connor Campbell said. Pandora A/S jumped 6.6% to the top of the STOXX 600 index on Tuesday after the Danish jewellery maker maintained its full-year guidance. However, a fall in bank shares and miners capped gains.

Read Full Details

Topics:
  • Business
  • Financial
  • Entertainment
News

FTSE 100 edges up on AstraZeneca boost

AZN AZN

(For a live blog on European stocks, type LIVE/ in an Eikon news window). * AstraZeneca up 1.5% as diabetes drug meets study goals. Aug 20 (Reuters) - London's FTSE 100 inched higher in early deals on Tuesday, as AstraZeneca advanced after its diabetes drug Farxiga met the main goal of a heart failure study, offsetting a post-earnings drop for miner BHP. The mid-cap FTSE 250 also gained 0.2% by 0709 GMT. AstraZeneca rose 1.5% and was the biggest boost to the blue-chip index after the results of the Farxiga study.

Read Full Details

Topics:
  • Business
  • Financial
News

AstraZeneca's Farxiga clears late-stage heart-failure study

AZN AZN

Visit our Privacy Policy to learn more or manage your personal preferences in our Cookie Consent Tool. AstraZeneca's Farxiga clears late-stage heart-failure study. (Reuters) - British drugmaker AstraZeneca Plc said on Tuesday that its diabetes drug Farxiga was successful in reducing the risk of death by heart attack or the worsening of a type of heart failure in a late-stage study. Farxiga met the main goal of the DAPA-HF trial which tested the treatment in addition to the standard treatment in patients whose heart cannot pump enough blood and included those with or without type-2 diabetes, the company said. The results are welcome news for AstraZeneca after regulators in the United States declined to approved Farxiga for use as a supplement to insulin in adults with type-1 diabetes where insulin alone was not able to control blood sugar levels.

Read Full Details

Topics:
  • Business
  • Health
  • Financial